Envofolimab and Lenvatinib in Combination With Gemcitabine Plus Cisplatin for Patients With Advanced Biliary Tract Cancer as First-Line Treatment: A Single-arm, Open-label, Phase II Study
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
This is a phase 2, single-arm, open label study. The purpose is to investigate both the efficacy and safety of Envofolimab and Lenvatinib in combination with Gemcitabine plus Cisplatin for treatment of advanced biliary tract cancer as first-line treatment.
详细描述
The trial will recruit 43 patients. At the first step, 10 patients will be recruited. Only when at least 4 patients achieve objective response will the trial enter the second step and continue to recruit other patients. After being enrolled, all patients giving written informed consent will receive treatment until progression of disease, unacceptable toxicity or death. The tumor response evaluation will be conducted on a regular basis until progression of disease. Long-term survival follow up will be conducted as well.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent obtained from the patient prior to treatment.
- •Age > 18 years at the time of study entry.
- •Pathologically confirmed advanced biliary tract cancer, not having received systemic therapy.
- •Measurable or evaluable lesions according to RECIST v1.1 criteria.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Life expectancy ≥ 12 weeks.
- •Adequate hematologic (absolute neutrophil count ≥ 1,500/μL, platelets count ≥ 100,000/μL, hemoglobin ≥ 9.0 g/dL), renal (serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault), urinary protein < 2+ or ≤ 1g/24h) and hepatic function (total serum bilirubin ≤ 1.5 ×ULN, serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤ 2.5 × ULN).
- •Normal coagulation function (INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN, PT ≤ 1.5 × ULN), without active bleeding or thrombotic diseases.
- •Willingness and ability to comply with the protocol.
排除标准
- •Diagnosis of any second malignancy, except for adequately treated basal cell skin cancer or in situ carcinoma of the cervix uteri.
- •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
- •Previous treatment with Chinese herbal medicine or immunomodulators within 2 weeks, or radiotherapy treatment within 4 weeks prior to the first dose of administration.
- •Abnormal thyroid function.
- •Uncontrolled hypertension.
- •Uncontrolled cardiac disease, including but not limited to heart failure (NYHA class II-IV), unstable angina pectoris, myocardial infarction within 1 year or cardiac arrhythmia.
- •Active or prior documented autoimmune or inflammatory disorders.
- •Any immunosuppressants or systemic steroid therapy (> 10 mg daily dose of prednisone or equivalent) within 2 weeks prior to enrollment.
- •Central nervous system metastases.
- •Active infection or unknown fever(>38.5℃) prior to the first dose of administration, except for cancerous fever.
- •History of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-associated pneumonia or severely impaired lung function.
- •Inherited or acquired immunodeficiency disease, including but not limited to infection of HIV or active hepatitis (HBV DNA ≥ 1000 IU/ml or HCV RNA ≥ 1000 IU/ml).
- •Live vaccine administration within 4 weeks prior to the first dose of administration or probably during the study.
- •History of psychotropic substance abuse, alcohol abuse, or drug use.
- •Pregnancy or lactation
- •Exclusion from the study by the judgement of investigator, due to some factors that may lead to the forced termination of the study.
研究组 & 干预措施
Envofolimab + Lenvatinib + Gemcitabine + Cisplatin
Single-arm trial whereby all consented, enrolled, eligible patients receive Envofolimab, Lenvatinib, Gemcitabine and Cisplatin
干预措施: Envofolimab (Drug)
Envofolimab + Lenvatinib + Gemcitabine + Cisplatin
Single-arm trial whereby all consented, enrolled, eligible patients receive Envofolimab, Lenvatinib, Gemcitabine and Cisplatin
干预措施: Lenvatinib (Drug)
Envofolimab + Lenvatinib + Gemcitabine + Cisplatin
Single-arm trial whereby all consented, enrolled, eligible patients receive Envofolimab, Lenvatinib, Gemcitabine and Cisplatin
干预措施: Gemcitabine (Drug)
Envofolimab + Lenvatinib + Gemcitabine + Cisplatin
Single-arm trial whereby all consented, enrolled, eligible patients receive Envofolimab, Lenvatinib, Gemcitabine and Cisplatin
干预措施: Cisplatin (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: Up to 2 years
ORR is defined as the percentage of patients who have achieved complete response (CR) or partial response (PR), as measured by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
次要结局
- Overall Survival (OS)(Up to 2 years)
- Progression-Free Survival (PFS)(Up to 2 years)
- Disease control rate (DCR)(Up to 2 years)
- Incidence of Adverse Events (AE)(Up to 2 years)
研究者
Ming Kuang
Professor
Sun Yat-sen University